The associations among quantitative spectral CT parameters, Ki-67 expression levels and EGFR mutation status in NSCLC
"Liaoyi Lin, JiejunCheng, DaoqiangTang, Ying Zhang, Feng Zhang, JianrongXu, Handong Jiang, HuaweiWu"

"spectral CT parameters may be useful for predicting

Ki-67 expression and the presence of EGFR mutation in NSCLC."

Sci Rep. 2020 Feb 26;10(1):3436. 

Effect of Tumor Location on Clinicopathological and Molecular Markers in Colorectal Cancer in Eastern China Patients: An Analysis of 2,356 Cases
Yaolin Song, Lili Wang, Wenwen Ran, Guangqi Li, Yujing Xiao, Xiaonan Wang, Li Zhang and Xiaoming Xing

In our study, we found that LCRC and RCC showed different features on the clinicopathological and molecular markers in eastern China CRC patients.

Front. Genet., 25 February 2020

Pulmonary Peripheral Glandular Papilloma and Mixed Squamous Cell and Glandular Papilloma Frequently Harbor the BRAF V600E Mutation
DongLiang Lin, XiaoMing Xing, WenWen Ran, Han Zhao, GuangQi Li, Jin Xu, Yan Wang, ShiHong Shao, JiGang Wang

Overlapping morphologic features and comparable mutation profiles support that peripheral GPs/MPs and CMPTs/BAs are on the same disease spectrum. We propose expanding the concept of CMPT/BA and including GP and MP in the CMPT/BA family.

Histopathology. 2020 Feb 25. 

Heterogeneous components of lung adenocarcinomas confer distinct EGFR mutation and PD-L1 expression
Yiran Cai, Hongbo Wu, Xiaoqin Shi, Yujie Dong, Xiujun Chang, Li Zhang, Lijuan Zhou, Dan Su & Ming Yang

"Intratumoral genetic heterogeneity of LACs was demonstrated associated with histological patterns.
Heterogeneous PD-L1 expression in higher level usually occurred in solid component both in EGFR mutated and EGFR
wild-typed LACs. EGFR mutated LACs heterogeneously had sensitizing and resistant mutation and was accompanied
with PD-L1 expression, but discordant among histological constituents. Immune checkpoint inhibitor combined with
third generation EGFR tyrosine kinase inhibitor should be more effective to these LACs."

BMC Cancer. 2020 Feb 24;20(1):148. 

Biomarker testing for personalized, first-line therapy in advanced nonsquamous non-small cell lung cancer patients in the real world setting in Japan: a retrospective, multicenter, observational study (the BRAVE study)
Junichi Shimizu, Katsuhiro Masago, Haruhiro Saito, Kazumi Nishino, Takayasu Kurata, Yohji Itoh, Yoko Yoshimura, Yutaka Yabuki, Hirotoshi Dosaka-Akita

The proportion of nonsquamous NSCLC patients with confirmed biomarker status for first-line treatment was considered insufficient and in need of improvement.

Ther Adv Med Oncol. 2020 Feb 22;12:1758835920904522.  

ALK detection in lung cancer: identification of atypical and cryptic ALK rearrangements using an optimal algorithm
Yuanyuan Liu, Shafei Wu, Xiaohua Shi, Zhiyong Liang, Xuan Zeng

False negative of ALK IHC, FISH and NGS results were found in our cohort, but none was false ALK positive. False ALK negatives should be more concerned than false positives. ALK rearrangements with cryptic ALK fusion patterns could be identified using our algorithm. Non-squamous non-small cell lung cancer was recommended for priority detection.

J Cancer Res Clin Oncol. 2020 Mar 3.